The FDA records supplied here identify the applicant as Roche and describe a single device family: the cobas EGFR Mutation Test, later styled cobas EGFR Mutation Test v2.0. The original approval, P120019, was decided on 14 May 2013 and describes a real-time PCR test for qualitative detection of exon 19 deletions and the exon 21 L858R substitution in the EGFR gene, using DNA from formalin-fixed paraffin-embedded human non-small cell lung cancer tumor tissue. Specimens are processed with the cobas DNA Sample Preparation Kit for manual preparation and the cobas z 480 Analyzer for automated amplification and detection. [3][1][2]
The approved device and its stated components
The P120019 approval order states that the test is intended as an aid in selecting patients with metastatic NSCLC for whom Tarceva (erlotinib), an EGFR tyrosine kinase inhibitor, is indicated. The same order names the sample preparation kit and the cobas z 480 Analyzer as the processing and detection components. The generic name recorded across the filings is somatic gene mutation detection system, with product code OWD and the Pathology advisory committee. [3][1][2]
Recent supplement activity on P120019
Two 2026 supplements appear in the supplied record sample. P120019/S045, a Special (Immediate Track) labeling change, was received 6 October 2026 and decided 4 November 2026 as APPR; its approval order statement covers updates to hazard information on the product labeling for the cobas DNA Sample Preparation Kit, a component of the cobas KRAS Mutation Test, cobas BRAF V600 Mutation Test and cobas EGFR Mutation Test v2.0. P120019/S044, a 30-Day Notice for a manufacturing process change to oligonucleotides, was received 30 September 2026 and decided 27 October 2026 as OK30. [1][2]
A separate v2 approval
The cobas EGFR Mutation Test v2 also carries its own PMA, P150044, received 23 November 2015 and decided 28 September 2016, with the applicant listed as Roche Molecular Systems, Inc. at 4300 Hacienda Dr., Pleasanton, CA. The FDA summary of safety and effectiveness data for P150044 records priority review granted 15 December 2015 and describes use of the test in detecting the EGFR T790M substitution mutation in EDTA plasma specimens, with bridging-study specimens drawn from the AstraZeneca AURA1 Ext and AURA2 studies. The same summary notes that AURA2 supported approval of the v2 test using FFPET specimens under P120019/S007. [6][9][10]
How to read the supplied counts
The supplied collection holds three linked PMA records, with decision counts of two APPR and one OK30. The smaller record sample of three entries shows the same split of two APPR and one OK30. These figures describe the supplied filings as of 20 November 2026 and are not measures of total company portfolio, sales or safety performance. No recall records were supplied. [1][2][3]



